Whitehawk Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Morning, everyone. Welcome to 2026 Global Healthcare Conference, Jefferies in London. My name is Roger Song, senior analyst, cover SMID biotech. It is my pleasure to have the fireside chat with our company, Whitehawk Therapeutics. We have the whole team here, Dave, Scott, and Margaret.
Welcome. Thanks, Roger. Great to be here, and thanks for Jefferies for hosting us.
Excellent. Okay. Dave, we chatted a little bit before the fireside chat. 2027 going to be very exciting for Whitehawk, and it's been a while since you acquired three ADC assets. You work pretty hard for a while. Now it's the moment. You will have a data readout from all of those three next year, two from the first half, and one in the second half by the end of the year. Before we talk, dive deep into those, can you give us a state of art of Whitehawk, where you're coming from, and how excited you are about 2027?
Thank you. Yeah. Whitehawk formed a little under two years ago with the in-licensing of a three ADC portfolio from WuXi Biologics.
That ADC portfolio is based on some unique underlying linker payload technology that we're really excited and think is differentiated in the space due to the stability that it provides. It is a topoisomerase-based platform, and therefore competing in this kind of advanced next-generation set of ADCs that are coming to market. We have some unique targets that we're going after with each asset, and we'll talk about those in a second. But it's been an exciting, really, two years now to bring those from preclinical. We filed our first two INDs the end of last year, our third IND earlier this year.
And now, for a company our size to have three assets in the clinic with data readouts on our first dose escalation data in 2027, it's a really exciting point to be.
Excellent. All right. I think we have 20-plus minute, we have three assets. Probably we should be more focused. Maybe the PTK7 and then MUC16 will be the focus of the conversation. Then start with the PTK7. So you mentioned this is differentiated, particularly on the linker payload side. Maybe just specifically for this asset, the target-wise, and then also the DAR, and then all the construct of the asset. Any differentiation you want to highlight before we talk about data?
Sure. Well, PTK7 is a really exciting ADC target because it's expressed on roughly about 70% of all cancers that you could address with an ADC, at least in the solid tumor space. So this is really a high-potential asset because of the number of cancers that you can go after. PTK7 otherwise is not expressed on healthy tissue to a large extent, and therefore makes it kind of an ideal target for ADCs. The linker payload system we utilize is called CPT113 and has a specific way that we actually bioconjugate the linker payload onto the antibody itself. But what it really allows for is a high degree of stability because of a particular aspect that no other company really uses, which is what we call Carbon Bridge Cysteine Re-pairing. It's a long name for a point that we basically add onto the ADC as a linked pair.
Okay. This actually stabilizes heavy-heavy and heavy-light chain interactions on the ADC, and allows for a more stable ADC construct in circulation.
In our hands, leads to the lowest free payload release that you're going to see, at least within comparative studies we can do within cynos. And therefore, we're really excited about the opportunity this has to provide great efficacy and limit the side effects that we've been seeing with a lot of other ADCs.
Excellent. I know we talk about this technology for a while, and then we have 100 ADC company out there. I think people end up appreciating how complex of the protein engineering for the different ADC platform. People will pay more attention to your technology once you have the good data, and people say, "Why?" Right? I think that's kind of where all the ADCs are coming from. Okay, talk about the exciting part of the clinical data next year. Can you tell us where's the enrollment right now, and then what should we expect to see? How much data we should expect to see at first half next year?
Yeah. Enrollment's going really well. We're happy with what we're seeing in terms of participation and engagement of the sites that we have. We have 17 active sites within the U.S., and are in the process of expanding to Asia and opening sites in multiple Asian countries, looking forward to dose expansion in the future. Ultimately, we're not going to say exactly where we are in dose escalation at this point, but we're happy with the progress that we've seen in enrollment.
Okay. When you report the data, will you be able to declare the recommended phase II dose, or what's this data cuts going to tell us in terms of the street and then the investors?
Right. We expect to have at least 20-30 patients worth of efficacy evaluable data across our dose escalation cohorts. We are utilizing backfills to improve the opportunity to accumulate a volume of patients to really start to assess not just the safety of the program, but some early efficacy signals. We expect to have dose escalation complete or near complete by the time we reveal data, and that would allow us to move into dose expansion on two doses that would ultimately form the RP2D.
Excellent. Okay. That's why it's very meaningful, data readout. Then you talk about the safety and then obviously the clinical activity. How much the PK and then also some of the technical part of the ADC you can also release us to tell us why this ADC could be very differentiated and potentially best in class?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
